Molecular Profiling for Non–Small-Cell Lung Cancer

For early-stage non–small-cell lung cancer (NSCLC), multimodality therapy is standard practice, but 5-year survival rates for stage II and III disease remain low (20%–40%). Molecular profiling has reshaped therapy in stage IV disease with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for EGFR-mutation patients. In addition, prior studies, specifically the 2006 IALT trial (N Engl J Med 2006; 355:983), demonstrated that high tumor levels of excision repair cross-complementation group 1 (ERCC1) immunohistochemistry (IHC) are predictive of cisplatin resistance.

To assess the feasibility of using EGFR mutation status and ERCC1 expression level to customize adjuvant NSCLC therapy, investigators conducted a phase II, multicente…